Buy 1809249-37-3 High Purity in stock

Superiority:

Buy 1809249-37-3 High Purity in stock

Remdesivir is a nucleoside analogue, an RNA-dependent RNA polymerase (RdRp) inhibitor that can synthesize antivirals by inhibiting viral nucleic acids. Clinical studies of Ebola virus infection are currently in phase II. Mice infected with MERS performed much better after receiving this combination therapy, with reduced viral replication and improved lung function. Recent studies have shown that Redsivir has an active role in suppressing new coronaviruses.

Product Advantage Introduction: Redsiwe is a nucleoside analogue developed by Gilead Sciences, and on May 7, 2020, the Japanese government approved Gilead Sciences (GILD. THE US) drug Redsivir has become the first officially approved drug in the country to treat new coronavirus-related diseases, giving priority to patients with severe illnesses. Redsiwe has not yet been licensed or approved outside of Japan, and in May 2020, Redsiwe was authorized by the U.S. Food and Drug Administration (FDA) for emergency use authorization (EUA). Although not yet approved by the FDA for official listing, but its Chemicalbook market prospects are very broad, and has a certain strategic drug value. Redsivir has broad-spectrum antiviral activity, and its in vitro and animal models have shown efficacy against a variety of emerging viral pathogens, including Ebola, Marburg, Middle East Respiratory Syndrome (MERS) and atypical pneumonia (SARS), so Redsievere is likely to play a therapeutic role in future outbreaks caused by similar viruses. At present, Redsiwe has been in the United States, Japan, the United Kingdom, the European Union, the United Arab Emirates, India and Canada and other 41 countries and regions have been approved for use in different forms.